Literature DB >> 112568

Nocturnal gastric drip feeding in glucose-6-phosphatase deficient children.

J Fernandes, H Jansen, T C Jansen.   

Abstract

UNLABELLED: Six patients with glucose-6-phosphatase deficiency were treated for 12 hr at night with gastric drip feeding (GDF), containing soy milk plus glucose, dextrimaltose, and starch. An alarm system (thermistor), connected to the gastric tube, was devised in case of displacement of the tube by the child. The effects of GDF were as follows. Base deficit and lacticaciduria decreased, but did not normalize. Serum cholesterol levels tended to normalize, but serum triglycerides remained elevated. The hepatic and extrahepatic components of plasma lipoprotein lipase were measured separately 5 and 40 min after iv heparin injection. Hepatic triglyceride lipase activities which were subnormal to normal increased to the lower normal range. Extrahepatic lipoprotein lipase activities, though increasing after GDF, remained abnormally low. Catch-up growth occurred in all four growth-retarded children. The pronounced liver enlargement of the five patients, not previously treated with GDF, decreased markedly. SPECULATION: Nocturnal GDF in glucose-6-phosphatase deficient children, suppresses the tendency for hypoglycemia and acidosis which are causes for stress, catabolism, and anorexia. By suppressing these factors, GDF promotes anabolism and caloric intake, thus accounting for the catch-up growth seen in the patients with growth retardation.

Entities:  

Mesh:

Year:  1979        PMID: 112568     DOI: 10.1203/00006450-197904000-00003

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients.

Authors:  P J Willems; W J Gerver; R Berger; J Fernandes
Journal:  Eur J Pediatr       Date:  1990-01       Impact factor: 3.183

2.  Biochemical evidence for the requirement of continuous glucose therapy in young adults with type 1 glycogen storage disease.

Authors:  J I Wolfsdorf; J F Crigler
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

3.  Glycogen storage disease type I. Results of treatment with frequent daytime feeding, combined with nocturnal intragastric feeding and with administration of an alpha-glucosidase inhibitor.

Authors:  H Gröbe; K Ullrich
Journal:  Eur J Pediatr       Date:  1983-04       Impact factor: 3.183

4.  Glycogenosis type Ib complicated by severe granulocytopenia resembling inherited neutropenia.

Authors:  C R Bartram; H Przyrembel; U Wendel; H J Bremer; J Schaub; J R Haas
Journal:  Eur J Pediatr       Date:  1981-09       Impact factor: 3.183

Review 5.  Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment.

Authors:  Y T Chen
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

6.  Patterns of growth in the hepatic glycogenoses.

Authors:  D B Dunger; J V Leonard; M A Preece
Journal:  Arch Dis Child       Date:  1984-07       Impact factor: 3.791

7.  Hyperglycaemia associated with lactic acidaemia in a renal allograft recipient with type I glycogen storage disease.

Authors:  Y T Chen; J I Scheinman
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

8.  Chronic pancreatitis in a child with glycogen storage disease type 1.

Authors:  M Kikuchi; K Hasegawa; I Handa; M Watabe; K Narisawa; K Tada
Journal:  Eur J Pediatr       Date:  1991-10       Impact factor: 3.183

9.  Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.

Authors:  Joanne A Hoogerland; Fabian Peeks; Brenda S Hijmans; Justina C Wolters; Sander Kooijman; Trijnie Bos; Aycha Bleeker; Theo H van Dijk; Henk Wolters; Albert Gerding; Karen van Eunen; Rick Havinga; Amanda C M Pronk; Patrick C N Rensen; Gilles Mithieux; Fabienne Rajas; Folkert Kuipers; Dirk-Jan Reijngoud; Terry G J Derks; Maaike H Oosterveer
Journal:  J Inherit Metab Dis       Date:  2021-04-07       Impact factor: 4.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.